Piramal Pharma Solutions (PPS) announced investment of US$55 million to expand its API manufacturing facilities.
State-of-the-art multi-purpose plants, with over 270kL of total capacity will be installed.
These plants will support the current pipeline of approximately 80 late-stage programs that PPS is currently assisting its partners with at various global sites.
The company will also expand its potency footprint (new Occupational Exposure Limit: ≥10 ng/m3) at its plant in Riverview, Michigan.
This expansion will also enhance early development capabilities adding GMP kilo labs and a pilot plant.
Piramal Pharma Solutions will add early development capabilities in both, drug substance and drug product.
It will have the support functions such as Analytical capabilities, R & D infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.
API development and manufacturing is supported through an integrated model across its five sites in North America, Europe, and Asia.
API Development activities include scouting and process development, which will be conducted at various facilities.
|Name||Piramal Pharma Solutions (PPS)|
|Parties Involved||Piramal Pharma Solutions (PPS)|